



AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September

Aug 23, 2018

REDWOOD CITY, Calif., Aug. 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that it will be featured as a presenting company and hosting investor meetings at the 20th Annual Rodman & Renshaw Global Investment Conference. Vince Angotti, CEO, will provide an overview of the business and updates during the live presentation and will be available for one-on-one meetings with investors. Members of the management team will also be attending the B. Riley FBR Healthcare Conference where it will be hosting investor meetings.

Details of the events are as follows:

B. Riley FBR Healthcare Conference

Date: Tuesday, September 4, 2018

Location: New York Marriott East Side, New York

20th Annual Rodman & Renshaw Global Investment Conference

Date: Thursday, September 6, 2018

Location: The St. Regis New York Hotel, New York

Presentation Time: 8:45am (Eastern Time)

The 20th Annual Rodman & Renshaw Global Investment Conference presentation will be webcast live and can be accessed through the Investors page at www.acerlx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acerlx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates in the United States including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso® (sufentanil sublingual tablet system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in hospitalized patients. DZUVEO™, as DSUVIA is known in Europe, and Zalviso are both approved products in Europe.

For additional information about AcelRx, please visit www.acerlx.com.



View original content with multimedia: <http://www.prnewswire.com/news-releases/acerlx-pharmaceuticals-to-participate-at-two-upcoming-investor-events-in-september-300701755.html>

SOURCE AcelRx Pharmaceuticals, Inc.

Brian Korb, Solebury Trout, 646-378-2923, investors@acerlx.com; Raffi Asadorian, Chief Financial Officer, AcelRx, investors@acerlx.com